1 Comparative study on the rheological properties and tablettability of various APIs

- 2 and their composites with titatane nanotubes
- 3
- 4 Barbara Sipos<sup>a</sup>, Géza Regdon jr.<sup>a</sup>, Zoltán Kónya<sup>b,c</sup>, Klára Pintye-Hódi<sup>a</sup>, Tamás
- 5 Sovány<sup>a</sup>\*
- <sup>6</sup> <sup>a</sup>University of Szeged, Institute of Pharmaceutical Technology and Regulatory Affairs,
- 7 Eötvös u. 6., H-6720, Szeged, Hungary
- <sup>8</sup> <sup>b</sup>University of Szeged, Department of Applied and Environmental Chemistry, Rerrich
- 9 Béla tér 1., H-6720, Szeged, Hungary
- <sup>10</sup> <sup>c</sup>Hungarian Academy of Sciences-University of Szeged, Reaction Kinetics and Surface
- 11 Chemistry Research Group, Rerrich Béla tér 1, H-6720, Szeged, Hungary

12

- 13 \* Corresponding author: Tamás Sovány
- 14 Fax: +36-62-545571, Tel.: +36-62-545576, E-mail: t.sovany@pharm.u-szeged.hu

15

## 18 1. Introduction

Titanate nanotubes (TNT) are newly explored and promising nanomaterials for a wide 19 20 range of medical applications. Among others, they show aptness to be used as radiosensitizer agents in radiotherapy [1], biocompatible biosensors [2] or cell viability 21 22 and proliferation enhancing materials for orthopaedic and periodontal use [3, 4]. 23 Besides, TNTs proved their capacity of being loaded with various active pharmaceutical 24 ingredients (API) and therefore came into focus of pharmaceutical research as carrier 25 materials [5, 6]. 26 Based on the experimental results, drug loaded TNTs may provide development in many issues of pharmaceutical sciences. On the one hand, TNTs carrying nano-sized 27 28 APIs may overcome fundamental difficulties related to the formulation and 29 manufacturing of nanocrystalline active substances, which may show an unavoidable tendency to autoaggregation, thereby worsening their physicochemical properties and 30 31 setting a limit to their commercialization. On the other hand, TNTs show an ability to achieve targeted drug delivery and controlled drug release, offering to put new and 32 33 modern medical therapies into practice [7, 8]. From this aspect, the outstanding 34 mechanical properties of TNTs may help to overcome formulation problems of other 35 nanocarriers such as dendrimers, micelles, liposomes, etc., which are available on the market, but their large-scale manufacturing, stabilization as well as their processing into 36 37 solid dosage forms require great efforts [9]. The present study aims to investigate the suitability of hydrothermally synthesized TNTs for the improvement of the processing 38 39 of nano-sized APIs into solid dosage forms with direct compression method. The structure of a tablet is influenced by many parameters, such as the physicochemical 40 properties of the compressed materials, the type of the tablet press, the applied 41

compression force, etc. [10]. When focusing on the materials, the understanding of the 42 43 behaviour of the compressed substances is essential for the commercial scale manufacturing of tablets. In order to reveal the tablettability of hydrothermally 44 45 synthesized TNTs and estimate their influence on the rheological properties of APIs, which is a completely new field in pharmaceutical research, a competitive study was 46 performed involving four APIs and their 1:1 ratio composites formed with TNTs. By 47 48 using an instrumented tableting machine, the monitoring of the compression cycle is feasible and with the help of statistical models flowability, particle rearrangement and 49 compressibility of the compressed materials are possible to be determined [11, 12]. In 50 51 the present study the Kawakita-Lüdde and Walker compression models were applied to estimate the compressibility characteristics and the deformation mechanism of the API 52 53 and API-TNT composite containing powder mixtures. The widely used Kawakita-54 Lüdde model [13] describes the volume reduction of the powder at a given compression pressure as a function of the pressure and therefore makes the analysis of particle 55 rearrangement and compactibility possible. However, it does not give much information 56 about the deformation mechanism of the powders, thus it is necessary to complement 57 the analysis with another model. The Walker model [14], which expresses the volume 58 59 reduction corresponding to a one-decade change in pressure, allows the characterisation of powder compressibility and therefore completes the Kawakita equation perfectly. 60 Although the calculated parameters can serve to predict the post-compressional 61 62 properties, tablets were investigated thoroughly in order to better understand the effects of TNT composite formation on tablet properties. 63

64

65 **2. Materials and methods** 

66 <u>2.1. Materials</u>

67	Diltiazem hydrochloride (DiltHCl), diclofenac sodium (DicNa), atenolol (ATN) and
68	hydrochlorothiazide (HCT) were kindly supported by Sanofi-Aventis PLC, Egis
69	Pharmaceuticals PLC, TEVA Pharmaceuticals PLC and Gedeon Richter PLC,
70	respectively. The following 1:1 ratio of active pharmaceutical ingredient (API)-
71	hydrothermally synthesized titanate nanotube (TNT) composites were produced by the
72	University of Szeged, Department of Applied and Environmental Chemistry: diltiazem
73	hydrochloride-TNT (DiltTi), diclofenac sodium-TNT (DicTi), atenolol-TNT (ATNTi),
74	hydrochlorothiazide-TNT (HCTTi). Excipients for tableting were Avicel PH 112 (FMC
75	Biopolymer Inc., USA), Tablettose 70 (Meggle Pharma GbbH, Germany), talc and
76	magnesium stearate.
77	
78	2.2. Preformulation study
79	The flowing properties of the APIs and the API-TNT composites were examined by a
80	software-controlled PTG-1 (Pharma Test Apparatebau AG, Germany) powder
81	rheological tester. A stainless-steel funnel with a 10-mm-diameter outlet nozzle was
82	filled with 100 ml of bulk powder and the powder flow was detected by IR sensors. The
83	equipment measured the flow time and calculated the angle of repose of the powder
84	heap.
85	Densification studies were performed for the APIs and the composites with a STAV
86	2003 Stampfvolumeter (Engelsmann AG., Germany). 250 ml of powder was put into a
87	graduated cylinder taking care that the powder does not pack. This volume served to
88	calculate the bulk density. The powder in the cylinder was mechanically tapped by the
89	apparatus at a speed of 1/sec until no further decrease in volume could be observed or
90	until tap number 1250 was reached. The volume of the densified powder was used to

92 (2)) values of the samples were determined as follows: 93 Hausner Ratio = $\rho T / \rho B$ (1)Compressibility Index =  $[(\rho T - \rho B)/\rho T)] * 100(\%)$ 94 (2)where  $\rho T$  is the tap density and  $\rho B$  is the bulk density of the powder in g/cm<sup>3</sup>. The 95 evaluation of the results was based on the USP scale of flowability [15]. 96 In order to determine the porosity of the APIs and the composites, the pycnometric 97 volume of the powders was measured with a Quantachrome Helium 98 Multipycnometer (Quantachrome GmbH, Germany). The porosity was calculated 99 100 by applying Eq. (3):  $\boldsymbol{\varepsilon} = [1 - (\boldsymbol{\rho B} / \boldsymbol{\rho P})] * 100$ 101 (3) where  $\varepsilon$  is the porosity (%),  $\rho T$  is the bulk density and  $\rho P$  is the pycnometric 102 density of the powder in g/cm<sup>3</sup>. 103 104 105 2.3. Tableting Tablets containing APIs and API-TNT composites were formulated. The compositions 106 107 of the tablets displayed in Table 1. were designed for constant tablet weight (300 mg) and quantity of API (50 mg) in order to respect the therapeutic goals and be 108 109 able to compare the API and API-TNT tablets according to the pharmaceutical requirements. 110 111 The powders were mixed with a Turbula (Willy A. Bachofen Maschienenfabrik, Switzerland) mixer at 50 rpm for 8 minutes without magnesium-stearate and for 2 112

calculate the tap density. The Hausner Ratio (Eq. (1)) and Compressibility Index (Eq.

91

113	minutes more with it. The weight of the tablets was designed to be about 300 mg. The
114	tablets were produced by the direct compression method with a Korsch EK0 (E. Korsch
115	Maschienenfabrik GmbH, Germany) eccentric tablet press, instrumented with strain
116	gauges and a displacement transducer. 10-mm-diameter flat punches were applied with
117	a compression force of 5.0, 7.5, 10.0, 12.5 and 15.0 kN for all the compositions.
118	
119	2.4. Compaction properties
120	The compaction properties of the powder mixtures (Table 1.) were estimated according
121	to the out-of-the-die method using the Kawakita and Walker models.
122	The Kawakita equation (Eq. (4)) was used to study the particle rearrangement of the
123	powder mixtures during the compression:
124	P/C = P/a + 1/ab  (4)
125	where <i>P</i> is the applied pressure <b>in MPa</b> , <i>C</i> is the degree of the volume reduction and <i>a</i>
126	and $b$ are constants. The degree of volume reduction is expressed by Eq. (5):
127	$C = (V_0 - V)/V_0$ (5)
128	where $V_0$ is the initial volume of the powder bed and V is the volume of the powder bed
129	at the applied pressure <b>in mm<sup>3</sup></b> .
130	Constant $a$ gives an indication of the initial porosity of the sample. Its higher value
131	presumes the loose packing of the powder in the die before compression. Constant $1/b$
132	describes the pressure which is needed to reduce the powder bed volume by 50%.
133	Higher coefficient $1/b$ implies higher cohesive energy of interaction, which shows up as
134	a hindered particle rearrangement.
135	The compressibility of the powder mixtures was investigated using the Walker (1923)
136	equations (Eq. (6) and (7)):
137	$\log P = -LV + C_1 \tag{6}$

 $100V = -W \log P + C$ (7)138 139 where P is the applied pressure in MPa, L is the pressing modulus which reflects the volume reduction at a given pressure, V is the relative volume, W is the Walker 140 141 coefficient which gives information about the volume reduction corresponding to onedecade change in the pressure, and C and  $C_1$  are constants. The relative volume is 142 expressed by Eq. (8): 143 144 V'/V<sub>0</sub> (8) where V' is the volume at the applied pressure and  $V_0$  is the initial volume of the powder 145 bed in  $mm^3$ . 146 147 148 2.5. Post-compressional properties 149 The mass, the thickness and the diameter of the prepared tablets were investigated with 150 a Kraemer UTS-50 (Charles Ischi AG, Switzerland) tablet testing system right after the production and one week later in order to follow the changes in the geometrical 151 152 parameters. 20 numbered tablets of each composition and compression force were 153 characterized. The parameters above served to calculate the apparent density of the 154 tablets. In addition to the apparent density, the study was completed with 155 pycnometric density measurements allowing the determination of tablet porosity (see the applied method under Section 2.2.) 156 The breaking strength of the tablets was studied with a Heberlein 2E/205 tablet hardness 157 158 tester (Heberlein AG, Switzerland), measuring 10 tablets per composition per compression pressure. In addition, the tensile strength of the tablets was calculated 159 using the following equation (Eq. (9)): 160

161  $\sigma = 2F/(\pi * d * h) \tag{9}$ 

162 where  $\sigma$  is the tensile strength in N, F is the breaking force in N, d is the diameter and h

is the height of the tablet **in mm**.

164 The texture of the prepared tablets was studied by taking Scanning Electron

165 Micrographs of the surface, while their breaking surface was examined with a

166 Hitachi S4700 (Hitachi Ltd., Japan) scanning electron microscope. The tablets

167 were stuck to a double-sided carbon adhesive tape and a conductive golden layer

168 was deployed with the use a sputter apparatus (Polaron Ltd., UK). The

169 measurements were performed at a magnification of 100-500, applying 10.0 kV of

- 170 electron energy and 1.3-13 MPa of air pressure.
- 171 The disintegration of the prepared tablets was investigated **in distilled water** with an
- 172 Erweka ZT71 (Erweka GmbH, Germany) disintegration tester apparatus according to
- the criteria of the Eur. Pharmacopoeia [16].

174 The drug release from the tablets was determined by an Erweka DT700 (Erweka

175 GmbH, Germany) dissolution tester, using the USP II method [17]. The dissolution

- 176 was tested at 37 °C, with pH 6.8 phosphate buffer as a dissolution medium. The 5-
- 177 ml aliquots were taken after 3, 5, 10, 15, 30, 60, 90, 120 minutes. The dissolved
- 178 drug (µg/ml) was defined with a ThermoScientific GENESYS 10S UV-VIS

179 spectrophotometer (Thermo Fisher Scientific Ltd., USA).

180

## 181 **3. Results and discussion**

- 182 <u>3.1. Preformulational properties of the APIs and the API-TNT composites</u>
- 183 Within the preformulation studies, the determination of the flow properties, the Hausner
- 184 Ratio and Compressibility Index values and the porosity of the samples was put into
- 185 focus (Table 2.). The results showed uniformity in that the composites displayed

preferable flow properties compared to the pure APIs, irrespective of the incorporatedAPI.

The measurements revealed that the APIs have extremely poor flow properties. In 188 189 contrast, favourable flowability was observed for the pure TNTs. As concerns the composites, the results are not consonant, the incorporation of DiltHCl and DicNa 190 191 induced better (measurable) flow time, while the composite formation of ATN and HCT 192 did not result in measurable flow time. This can be explained by the partially feasible 193 incorporation of ATN and HCT into TNTs [18]. Therefore, as ATNTi and HCTTi products contain individual API crystals, the flowability improving effect of TNTs 194 195 decreases or completely lags behind. The investigation of the particle rearrangement revealed an exponential-type 196 197 rearrangement profile for all the samples (Fig.1). Regarding the calculated Hausner 198 Ratio and Compressibility Index values, it is clearly visible that all the APIs reached an 199 upper range of the USP scale of flowability [15] by the incorporation. The flowability of 200 the composites varies between those of the component materials, which was expected 201 based on the fact that the APIs are located not only in the inner parts of TNTs but on 202 their surface as well [18]. The rate of the flowability improvement probably depends on 203 the ratio of the surface coverage. 204 The results of the pycnometric volume measurements confirmed that TNTs possess

notably high pycnometric density and high porosity, which was expected due to the tubular structure and the great number of interparticular pores between the nanosized particles. Accordingly, the porosity of the composites is also greater than that of the pure APIs: this phenomenon was more expressed for DiltTi and DicTi, where the drug incorporation was complete, and less (or not) expressed for the partially incorporated ATNTi and HCTTi products. It is also notable that HCTTi,

where TNTs are attached to the surface of the HCT particles [18], exhibits slightly
decreased porosity, which may be due to the decreasing number of interparticular
pores.

214

215 <u>3.2. Compaction properties of the API and API-TNT containing powder mixtures</u>

The tablettability of the powder mixtures was thoroughly investigated by using an
instrumented tablet press.

Knowing the degree of volume reduction under pressure, the particle rearrangement 218 of the powder mixtures was studied by using the Kawakita model. The results of the 219 220 analysis were plotted; the graphs of the DiltHCl and DiltTi tablets are presented in Fig. 2. The data fit the Kawakita model well with a  $R^2$  being at least 0.998. Constants a and 221 1/b, which were obtained from the graphs, are displayed in Table 3. 222 223 The values of constant a, which give information about the rearrangement of the 224 powders, are very similar for all the samples. Although the preformulation studies 225 presumed lower constant a values for the composite containing compositions, no 226 remarkable differences could be noticed either between the four API tablet compositions or between the API and the related API-TNT tablet compositions. This 227 228 result confirms the selection of an appropriate excipient profile for the tablets, resulting 229 in powder mixtures with nearly the same flow properties. However, the fact that the 230 compositions of the composites contain proportionally less excipient than those of the 231 APIs implies the better flowability of the composites. 232 The values of constant 1/b, which correlate with the cohesiveness, showed important differences between the API and API-TNT tablet compositions. Based on the several 233 234 times higher 1/b values of the composite containing powders, it is clear that the composite content requires much higher energy to reduce the volume of the powder to 235

236 half of the original. The low *l/b* values can be explained by the fast collapse of the 237 powders in the die, supporting our visual observations made during the preformulation studies. In contrast, powders with a high 1/b value exhibit continuous densification 238 239 under increasing load. It can be seen that the relation between the value of constant a of the HCT and the HCTTi tablet compositions is different, and the HCTTi containing 240 241 powder mixtures have a lower 1/b value than the HCT tablet composition. In order to 242 make this exceptional behaviour clear, the structural properties of the HCTTi product have to be taken into consideration. As it was already mentioned, the incorporation of 243 HCT into TNTs was not completely successful, resulting in a product which, besides the 244 245 aggregated composites, contains HCT crystals covered with TNTs [18]. Owing to the surface coverage, the HCTTi product displays higher surface free energy than the pure 246 247 HCT, therefore it shows superior adhesivity as well. For this reason, instead of 248 improving compactibility, the HCTTi product generates an unfavourable particle 249 rearrangement, showing an even worse compactibility profile than the pure API itself. 250 The compressibility of the compositions was examined by applying the Walker model. 251 From the plotted graphs (the graphs of DiltHCl and DiltTi tablets are shown in Fig. 3 and 4) coefficients L and W were defined. The data are presented in Table 3. 252 253 According to the results, coefficient L, also called pressing modulus, appeared to be 254 lower for the composite containing compositions, reflecting their higher volume 255 reduction at a given pressure compared to the tablet compositions containing pure API. 256 This behaviour is supported by the preformulation studies, during which the composites revealed higher density than the APIs, and also by the fact that the composite formation 257 results in smaller surface free energy [18]. The results of HCT and HCTTi tablet 258 259 powder mixtures showed up again oppositely, thus the HCTTi containing composition

260 displayed a higher coefficient *L* value. This result is in perfect accordance with our261 conception described above.

The obtained Walker coefficient values, which refer to the irreversible compressibility

of the powders, correspond with the results discussed so far. The higher values of

264 coefficient W shown by the composite containing compositions hint at plastic 265 deformation and better tableting properties. In contrast, the smaller W values of tablet 266 compositions containing pure API mark an extended densification maximum due to the high elastic recovery of the crystalline APIs. In this case again, the HCTTi composite 267 containing powder mixture showed opposing behaviour as compared to the other API-268 269 TNT tablet compositions, confirming the above-mentioned negative effect of the 270 unsuccessful composite formation. 271 Overall, it can be concluded that the incorporation of drugs into TNTs is advantageous

and results in more ideal compaction behaviour. However, it is also important to remark

that a partially successful composite formation may affect the compaction properties

- negatively, therefore the appropriate incorporation process plays a key role in this issue.
- 275

272

262

263

## 276 <u>3.3. Post-compressional properties of the API and API-TNT tablets</u>

277 The measurements of the geometric parameters allowed us to define the apparent

278 density of the tablets right after the compression and one week later as well. The results

are summarized in Table 4.

Based on the data, it can be stated that the tablet density generally increases with the

compression force. The only exception was shown by the ATN tablets, where the

- 282 density measured right after compression decreased with the increase of the
- compression force. This phenomenon can be explained by the strong elasticity of ATN,
- which results in a rising elastic recovery with the increase of the compression force.

285 This conception is supported by the low value of coefficient W received from the 286 Walker analysis (Table 3.). Nevertheless, the density values measured after one-287 week storage show that the bonds in the ATN containing tablets undergo a considerably high consolidation during the first period of storage, which may also 288 289 be observed in the case of other elastic systems [19]. It is also noteworthy that this 290 phenomenon did not appear for the ATNTi tablets, which shows the positive effect of 291 TNTs on elastic recovery. 292 It can also be established from the data that the apparent density of the API-TNT tablets 293 is higher than that of the API tablets for all the investigated compression forces. 294 However, in the case of DicNa and DicTi tablets this statement is relevant only at higher

compression forces, which supports the good rearrangement and compressibility

296 properties of DicNa seen in Table 3. Nevertheless, it can be concluded that the presence

297 of TNTs generally increases the apparent tablet density.

It is also necessary to consider the post-compressional apparent density changes as they

299 can provide further information about the processability of the APIs and their

300 composites. The density of the DiltHCl tablets decreased in time at each compression

301 force, while the density of the DicNa, ATN and HCT tablets increased during the one-

302 week storage. The decrease in density is probably due to the release of the stored stress

by the tablet by increasing its volume, while the increase of tablet density is probably

the result of the consolidating bonding forces. Regarding the API-TNT tablets, in the

305 case of DiltTi and DicTi the density did not change at lower compression forces and

306 only barely decreased beyond 10.0kN in time. These results support the plastic

307 deformation of these composite containing compositions inducing stable tablet density

308 at low compression forces and only slight changes in density at high compression

309 pressure. On the other hand, the apparent density of the ATNTi and HCTTi tablets was

310 noticed to increase during the one-week storage at all compression forces. These results 311 showing similarity to those of the ATN and HCT tablets certainly originate in the incomplete incorporation of these materials into TNTs. Furthermore, in the case of the 312 313 HCTTi tablets it was also predictable based on the compaction studies. As regards the true density and the porosity of the tablets (Table 5.), those 314 containing composites showed higher true density than API tablets, which is in 315 316 accordance with the presented apparent densities as well as with the expectations built on the powder porosities shown in Table 2. The porosity of the tablets, which 317 constantly decreased with the increase of the compression pressure, exhibits 318 319 considerable differences with regard to the compressibility and the texture of the 320 compositions. According to the preformulation results, all the composites have higher porosity than the pure APIs, due to the tubular structure of TNTs. This 321 322 difference is clearly visible also for tablets prepared from composites which exhibit poorer compressibility (DicTi and ATNTi), while tablets prepared from DiltTi, 323 324 which showed superior compressibility, have lower porosity than the 325 corresponding DiltHCl tablets at all compression forces. A slight decrease of 326 porosity may also be observed for the HCTTi tablets, but this can be due to the 327 unique structure of the composite and not to the good compressibility of the composition. 328 The forces required to break the tablets and the calculated tensile strength values are 329 330 displayed in Table 6. As expected, the breaking strength increases with the compression force in all the cases. 331 332 Based on the results, it is outstanding that the breaking strength of the API-TNT tablets is much superior to that of the API tablets at all compression forces. Moreover, in 333 consonance with the results of the compaction measurements, the API-TNT tablets 334

335 display a greater increase in breaking strength between 5.0 and 15.0 kN compression 336 force than the API tablets. According to the data, the less influence of the incorporation on the breaking strength was observed for DicNa, where a difference of 3.0 N could 337 338 only be detected in the breaking strength of DicNa and DicTi tablets at 5.0 kN compression force. Although this difference slightly increased with the compression 339 340 force, it was not remarkable at 15.0 kN either. This observation is in agreement with the 341 results of the apparent density measurements. Comparing the four APIs, HCT (and 342 therefore HCTTi) tablets showed the biggest breaking strengths at each compression 343 force. In accordance with the high apparent density values displayed in Table 4., these 344 results prove their greater hardness compared to the other samples. The disintegration time of the API and API-TNT tablets was investigated in order to 345 346 reveal the effect of the composite formation on the disintegration and therefore its 347 impact on drug dissolution. The results of the measurements are shown in Table 6. As expected, the disintegration time rose with the compression pressure in all the cases. 348 349 When comparing the API and API-TNT tablets, it can be stated that the disintegration 350 of the composite containing tablets is slower at each investigated compression pressure. 351 The superior disintegration times of the API-TNT tablets refer to their greater hardness, 352 confirming the findings of the above post-compression studies. 353 The most considerable effect of the incorporation on the disintegration time was seen 354 for the ATN tablets as a result of the important difference in strength observed between 355 the ATN and ATNTi tablets. It is noteworthy that the partial incorporation of HCT is 356 clearly reflected in the results: the HCT and HCTTi tablets show similar disintegration 357 time values. It is also interesting to note that despite their high hardness and apparent 358 density, the HCT and HCTTi tablets disintegrate very quickly and, in contrast with the 359 other compositions, their disintegration is less dependent on the compression pressure.

360 The scanning electron micrographs of the tablets (Fig. 5.) support the results of the 361 compressibility studies, according to which the HCT and HCTTi tablets go through a considerably higher densification already at lower compression forces, resulting in 362 363 smaller porosity. The SEM pictures also reveal that the irregular densification may be due to the fragmentation of the HCT particles, which may also be an explanation for the 364 365 fast disintegration process. The water penetrating into the microfractures (marked with 366 white arrows) of the HCT particles disrupts the fractures and the released energy 367 enhances the disintegration process.

The results of the dissolution tests are presented in Fig. 6. In general, slower drug 368 369 release may be observed from the API-TNT tablets than from the related API tablets in all the cases. This may be explained by the slower disintegration, due to 370 the higher breaking strength and density of these tablets, independently from their 371 372 porosity. This may support the conclusion that the observed porosity differences between the APIs and the composites are due to the tubular structure of TNTs and 373 374 not to the looser tablet skeleton. It is important to note that the occurrence of strong interactions may also change the kinetics of the drug release, as observed in 375 376 the case of DicNa, where the first order drug dissolution from the DicNa tablets 377 changed to prolonged dissolution based on Korsmeyer-Peppas kinetics from the DicTi tablets. In accordance with the expectations, the speed of dissolution 378 379 decreased with the increase of the compression force in the case of the API and 380 API-TNT tablets as well. However, it could be seen that this slowing down of dissolution was more intense for the API-TNT tablets, confirming the especially 381 good compressibility and compactibility of the composites. 382

383

384 **4.** Conclusion

The present study aimed to determine the effect of 1:1 ratio API-TNT composite formation on the tablettability of the incorporated API. Four different composite products were used to obtain reliable results.

388 The preformulation measurements revealed that the composite formation with TNTs

highly improved the extremely poor flowability of the APIs. This positive effect of

390 TNTs on powder rheology was proved for all the investigated APIs, indicating

promising opportunities for developing drug processability with the use of TNTs.

However, the rate of flowability improvement was seen to be dependent on the

efficiency of the incorporation process; ATNTi and HCTTi showed slighter flowabilityimprovement.

When comparing the compaction properties of the API and API-TNT tablets, it was 395 396 seen that the composite formation resulted in better compactibility, showing higher 397 volume reduction at a given compression pressure. Furthermore, drug incorporation into 398 TNTs hindered the elastic recovery of the APIs and led to plastic deformation. These 399 results confirmed the great advantage of composite formation for manufacturing tablets 400 with direct compression. On the other hand, the measurements also revealed that 401 inappropriate incorporation may also affect the compaction behaviour of the API 402 negatively, as observed for HCT. Accordingly, the successfulness of the incorporation 403 is considered to be the key factor of the tablettability improving effect of TNTs. 404 In accordance with the more ideal compaction behaviour, the API-TNT tablets showed 405 better post-compressional properties than the tablets containing pure APIs, displaying 406 higher apparent density, superior breaking strength and slower disintegration at all the applied compression forces. The greater strength of the API-TNT tablets compared to 407 408 that of the pure APIs was observed for all the APIs without reference to the efficacy of 409 the incorporation.


410	Overall, the present work revealed that the appropriate incorporation of APIs into TNTs
411	highly improves their tablettability and results in tablets with favourable mechanical
412	properties. Accordingly, it can be concluded that hydrothermally synthesized TNTs can
413	advantageously be used as drug carriers in the manufacturing of tablets with direct
414	compression.
415	
416	Acknowledgements
417	The authors would like to thank Péter Kása jr. for taking the SEM pictures.
418	
419	Conflict of Interest
420	The authors declare that there is no conflict of interest regarding the publication of this
421	paper.
422	
423	References
424	[1] C. Mirjolet, A. Papa, G. Créhange, O. Raguin, C. Seignez, C. Paul, G. Truc, P.
425	Maingon, N. Millot, The radiosensitization effect of titanate nanotubes as a new tool in
426	radiation therapy for glioblastoma: A proof-of-concept, Radiotherapy and Oncology
427	108 (2013) 136-142.
428	[2] R. Zhao, X.Liu, J. Zhang, J. Zhu, D. K. Y. Wong, Enhancing direct electron transfer
429	of glucose oxidase using a gold nanoparticle/titanate nanotube nanocomposite on a
430	biosensor, Electrochimica Acta 163 (2015) 64–70.
431	[3] S. Beke, R. Barenghi, B. Farkas, I. Romano, L. Kőrösi, S. Scaglione, F. Brandi,
432	Improved cell activity on biodegradable photopolymer scaffolds using titanate nanotube
433	coatings, Materials Science and Engineering: C 44 (2014) 38-43.

- 434 [4] E. Kato, K. Sakurai, M. Yamada, Periodontal-like gingival connective tissue
- 435 attachment on titanium surface with nano-ordered spikes and pores created by alkali-
- 436 heat treatment, Dental Materials 31 (2015) 116–130.
- 437 [5] K. Indira, U. KamachiMudalib, N. Rajendran, In vitro bioactivity and corrosion
- 438 resistance of Zr incorporated TiO2 nanotube arrays for orthopaedic applications,
- 439 Applied Surface Science 316 (2014) 264–275.
- 440 [6] A. L. Doadrio, A. Conde, M. A. Arenas, J. M. Hernández-López, J. J. de
- 441 Damborenea, C. Pérez-Jorge, J. Esteban, M. Vallet-Regí, Use of anodized titanium
- 442 alloy as drug carrier: Ibuprofen as model of drug releasing, International Journal of
- 443 Pharmaceutics 492 (2015) 207-12.
- 444 [7] Y. Zhang, L. Chen, C. Liu, X. Feng, L. Wei, L. Shao, Self-assembly chitosan/gelatin
- 445 composite coating on icariin-modified TiO2 nanotubes for the regulation of osteoblast
- 446 bioactivity, Materials & Design 92 (2016) 471-479.
- 447 [8] T. Kumeria, H. Mon, M. S.Aw, K. Gulati, A. Santos, H. J. Griesser, D. Losi,
- 448 Advanced biopolymer-coated drug-releasing titania nanotubes (TNTs) implants with
- simultaneously enhanced osteoblast adhesion and antibacterial properties, Colloids and
- 450 Surfaces B: Biointerfaces 130 (2015) 255–263.
- 451 [9] A. Elhissi, D. Phoenix, W. Ahmed, Some approaches to large-scale manufacturing
- 452 of liposomes, Emerging Nanotechnologies for Manufacturing, second ed., William
- 453 Andrew, 2015
- 454 [10] Ch. Mao. V. R. Thalladi, D. K. Kim, S. H. Ma, D. Edgren, S. Karaborni,
- 455 Harnessing ordered mixing to enable direct-compression process for low-dose tablet
- 456 manufacturing at production scale, Powder Technology 239 (2013) 290–299.
- 457 [11] T. Osamura, Y. Takeuchi, R. Onodera, M. Kitamura, Y. Takahashi, K. Tahara, H.
- 458 Takeuchi, Characterization of tableting properties measured with a multi-functional


- 459 compaction instrument for several pharmaceutical excipients and actual tablet
- 460 formulations, International Journal of Pharmaceutics 510, Issue 1 (2016) 195–202.
- 461 [12] A. Hadadzadeh, M. A. Whitney, M. A. Wells, S. F. Corbin, Analysis of
- 462 compressibility behavior and development of a plastic yield model for uniaxial die
- 463 compaction of sponge titanium powder, Journal of Materials Processing Technology
- 464 243 (2017) 92–99.
- 465 [13]A. Persson, J. Nordström, G. Frenning, G. Alderborn, Compression analysis for
- 466 assessment of pellet plasticity: Identification of reactant pores and comparison between
- 467 Heckel, Kawakita, and Adams equations, Chemical Engineering Research and Design
  468 110 (2016) 183–191.
- 469 [14] S. Mallick, Rearrangement of particle and compactibility, tabletability and
- 470 compressibility of pharmaceutical powder: A rational approach, Journal of Scientific &
- 471 Industrial Research 110 (2016) 183–191.
- [15] United States Pharmacopeia Convention, Pharmacopeia and National
  Formulary (USP 29 NF 24), General Chapters: <1174> POWDER FLOW,
  United States Pharmacopeia Convention, Inc., Rockville, MD, United States
  (2000), 3017.
- [16] Council of Europe, European Pharmacopoeia, 5th ed. Main volume 5.0,2.9.1.
  Disintegration of tablets and capsules, Council of Europe, Strasbourg (2004) 225227.
- 479 [17] United States Pharmacopeia Convention, Pharmacopeia and National
  480 Formulary (USP 29 NF 24), General Chapters: <711> DISSOLUTION, United
- 481 States Pharmacopeia Convention, Inc., Rockville, MD, United States (2000) 2673.
- 482 [18] B. Sipos, K. Pintye-Hódi, Z. Kónya, A. Kelemen, G. Regdon jr., T. Sovány,
- 483 Physicochemical characterisation and investigation of the bonding mechanisms of API-


- 484 titanate nanotube composites as new drug carrier systems, International Journal of
- 485 Pharmaceutics 518 (2017) 119–129.
- 486 [19] I. Jójárt, A. Kelemen, P. Kása jr., K. Pintye-Hódi, Tracking of the post-
- 487 compressional behaviour of chewing gum tablets, Composites Part B: Engineering, 49
- 488 (2013) Pages 1-5


- 492 Figure captions
- 493 Figure 1: Particle rearrangement profile of TNTs, APIs and API-TNT composites
- 494 Figure 2: Kawakita-Lüdde plot of DiltHCl and DiltTi containing powder mixtures
- 495 Figure 3: Walker W plot of DiltHCl and DiltTi containing powder mixtures
- 496 Figure 4: Walker L plot of DiltHCl and DiltTi containing powder mixtures
- 497 Figure 5: SEM micrographs of tablets (DicTi 5kN tablet surface (a) and breaking
- 498 surface (b); DicTi 15kN tablet surface (c), breaking surface (d); HCTTi 5 kN tablet
- 499 surface (e), breaking surface (f); HCTTi 15 kN tablet surface (g), breaking surface
- 500 (**h**))
- 501 Figure 6: Drug dissolution from API and API-TNT tablets compressed with 5.0,
- 502 7.5, 10.0, 12.5 and 15.0 kN in pH 6.8 phosphate buffer


















Figure(s) Click here to download high resolution image



Materials	API tablets	API-TNT tablets
API	16.7%	-
API-TNT	-	33.3%
Avicel PH 112	50.0%	39.5%
Tablettose	29.3%	23.2%
Talc	3.0%	3.0%
Mg-stearate	1.0%	1.0%

Table 1. Composition of API and API-TNT tablets

	Flow time	Angle of	Bulk density	Tapped density	Pycnometric density	Porosity	Hausner	Compressibility	Flowability
Material	(sec)	repose (°)	(g/cm^3)	(g/cm^3)	(g/cm^3)	(%)	Ratio	Index (%)	(USP scale)
TNT	14.3	25.5	0.65	0.76	3.02	78.51	1.17	14.47	good
DiltHCl	n.m.	-	0.45	0.59	1.30	65.34	1.31	23.73	passable
DiltTi	16.5	28.2	0.51	0.64	1.78	71.39	1.25	20.31	fair
DicNa	n.m.	-	0.48	0.73	1.50	68.01	1.52	34.25	very poor
DicTi	6.3	28.4	0.55	0.68	1.97	72.05	1.24	19.12	fair
ATN	n.m.	-	0.3	0.48	1.21	75.16	1.6	37.5	very very poor
ATNTi	n.m.	-	0.38	0.49	1.64	76.81	1.29	22.45	passable
HCT	n.m.	-	0.46	0.76	1.69	72.72	1.65	39.47	very very poor
HCTTi	n.m.	-	0.61	0.76	2.17	71.94	1.25	19.74	fair
			1.1						

Table 2. Preformulation results of the APIs and the API-TNT composites

n.m.=not measurable

Tablet	a	1/b	L	W
DiltHCl	0.68	8.03	7.9	11.59
DiltTi	0.62	18.63	5.93	16.49
DicNa	0.67	6.38	9.85	8.72
DicTi	0.68	13.53	6.64	14.73
ATN	0.64	5.94	13.56	4.04
ATNTi	0.65	17.61	8.47	9.43
HCT	0.61	14.32	12.89	7.01
HCTTi	0.68	6.04	17.76	2.49

Table 3. Parameters calculated from Kawakita and Walker plots

	API			Composite				
Pressing	0 h		168 h		0 h		168 h	
force (kN)	Apparent density	SD	Apparent density	SD	Apparent density	SD	Apparent density	SD
	DiltHCl				DiltTi			
5.0	1.09	0.01	1.06	0.01	1.23	0.01	1.23	0.00
7.5	1.18	0.01	1.15	0.01	1.30	0.00	1.30	0.00
10.0	1.25	0.01	1.23	0.01	1.35	0.02	1.35	0.01
12.5	1.29	0.01	1.27	0.01	1.40	0.01	1.39	0.00
15.0	1.30	0.07	1.28	0.08	1.42	0.00	1.40	0.00
	DicNa				DicTi			
5.0	1.16	0.01	1.16	0.01	1.16	0.00	1.16	0.01
7.5	1.23	0.02	1.26	0.02	1.23	0.01	1.23	0.02
10.0	1.27	0.01	1.32	0.02	1.32	0.00	1.32	0.00
12.5	1.30	0.01	1.35	0.02	1.36	0.01	1.35	0.02
15.0	1.34	0.01	1.40	0.01	1.42	0.00	1.40	0.04
	ATN				ATNTi			
5.0	1.11	0.01	1.25	0.01	1.15	0.01	1.31	0.01
7.5	1.04	0.01	1.28	0.01	1.20	0.01	1.37	0.00
10.0	1.01	0.01	1.28	0.01	1.23	0.01	1.40	0.01
12.5	0.93	0.00	1.30	0.01	1.24	0.01	1.42	0.01
15.0	0.92	0.01	1.32	0.01	1.25	0.02	1.43	0.01
	НСТ				HCTTI			
5.0	1.03	0.01	1.28	0.01	1.17	0.00	1.39	0.01
7.5	1.07	0.01	1.33	0.01	1.20	0.01	1.42	0.00
10.0	1.09	0.03	1.39	0.01	1.26	0.00	1.48	0.01
12.5	1.11	0.00	1.40	0.00	1.31	0.00	1.48	0.01
15.0	1.12	0.00	1.41	0.00	1.37	0.00	1.52	0.00

Table 4. Apparent density of the API and API-TNT tablets determined right afterthe preparation and one week later

<b>D</b>	True		D		True		Porosity	
Pressing	density	SD	Porosity (%)	SD	density	SD	(%)	SD
force (kN)	$(g/cm^3)$		(70)		(g/cm <sup>3</sup> )		(70)	
(KIN)		DiltHO	CI			Dil	t <b>Ti</b>	
5.0	1.0517	0.0098	29.41	0.45	1.6336	0.0080	24.70	0.36
7.5	1.0517	0.0098	23.42	0.49	1.6336	0.0080	20.42	0.38
10.0	1.0517	0.0098	18.09	0.53	1.6336	0.0080	17.35	0.40
12.5	1.0517	0.0098	15.43	0.54	1.6336	0.0080	14.91	0.41
15.0	1.0517	0.0098	14.76	0.55	1.6336	0.0080	14.29	0.41
		DicNa	l			Dic	Ti	
5.0	1.5426	0.0065	24.80	0.31	1.6685	0.0151	30.47	0.62
7.5	1.5426	0.0065	18.31	0.34	1.6685	0.0151	26.27	0.66
10.0	1.5426	0.0065	14.42	0.36	1.6685	0.0151	20.88	0.71
12.5	1.5426	0.0065	12.48	0.37	1.6685	0.0151	19.08	0.73
15.0	1.5426	0.0065	9.243	0.38	1.6685	0.0151	16.08	0.75
		ATN				ATN	NTi	
5.0	1.4721	0.0045	15.08	0.26	1.5953	0.0043	17.88	0.21
7.5	1.4721	0.0045	13.04	0.26	1.5953	0.0043	14.11	0.22
10.0	1.4721	0.0045	13.04	0.26	1.5953	0.0043	12.23	0.23
12.5	1.4721	0.0045	11.68	0.27	1.5953	0.0043	10.98	0.23
15.0	1.4721	0.0045	10.33	0.27	1.5953	0.0043	10.35	0.23
		НСТ				HC	ГТі	
5.0	1.5918	0.0038	19.55	1.87	1.6909	0.0289	17.77	1.39
7.5	1.5918	0.0038	16.40	1.94	1.6909	0.0289	16.00	1.42
10.0	1.5918	0.0038	12.63	2.03	1.6909	0.0289	12.45	1.49
12.5	1.5918	0.0038	12.01	2.05	1.6909	0.0289	12.45	1.49
15.0	1.5918	0.0038	11.38	2.06	1.6909	0.0289	10.08	1.53

Table 5. True density and porosity of the API and API-TNT tablets

Pressing	Breaking	CD	Tensile	CD	Breaking	CD	Tensile	CD
force	strength (N)	SD						
(kN)	DiltHCl				DiltTi			
5.0	24.9	1.1	0.47	0.02	69.0	1.79	1.42	0.04
7.5	53.0	3.63	1.09	0.06	96.0	2.37	2.08	0.05
10.0	66.2	4.47	1.60	3.68	122.0	4.86	2.83	0.09
12.5	104.0	4.53	2.35	0.08	142.0	2.66	3.37	0.06
15.0	124.0	3.19	2.83	0.10	156.0	2.86	3.79	0.05
	DicNa				DicTi			
5.0	42.9	2.64	0.85	0.05	46.0	3.04	0.93	0.05
7.5	58.1	3.68	1.21	0.08	66.0	2.80	1.44	0.05
10.0	81.2	4.58	1.74	0.07	99.0	3.63	2.27	0.08
12.5	98.1	3.91	2.17	0.08	120.0	3.30	2.83	0.07
15.0	125.0	3.00	2.73	0.07	153.0	3.05	3.80	0.06
	ATN				ATNTi			
5.0	79.5	2.90	1.68	0.06	102.0	4.56	1.99	0.09
7.5	82.4	2.08	1.75	0.04	121.0	1.97	2.48	0.05
10.0	89.6	1.60	1.99	0.04	138.0	2.77	2.88	0.05
12.5	101.0	4.27	2.02	0.09	141.0	2.19	3.00	0.05
15.0	102.0	3.08	2.13	0.08	149.0	4.34	3.24	0.09
	НСТ				HCTTi			
5.0	87.0	4.20	1.63	0.08	127.0	3.16	2.65	0.07
7.5	112.0	3.84	2.18	0.07	148.0.	3.64	3.14	0.07
10.0	149.0	4.81	2.92	0.20	190.0	3.10	4.13	0.07
12.5	153.0	3.40	3.10	0.06	191.0	3.50	4.32	0.08
15.0	160.0	4.00	3.22	0.10	222.0	2.72	5.14	0.06

Table 6. Breaking and tensile strength of the API and API-TNT tablets

Compressing	Disintegration	SD	Disintegration	SD
force (kN)	time(min)	50	time(min)	50
	DiltHCl		DiltTi	
5.0	0.16	0.02	0.52	0.03
7.5	0.41	0.17	2.44	0.29
10.0	8.28	0.68	9.54	0.49
12.5	11.07	1.34	15.49	0.27
15.0	18.13	0.52	18.46	0.52
	DicNa		DicTi	
5.0	0.20	0.01	1.34	0.09
7.5	0.41	0.05	2.13	0.05
10.0	1.05	0.13	3.21	0.41
12.5	1.58	0.19	4.26	0.65
15.0	4.23	0.05	5.27	0.37
	ATN		ATNTi	
5.0	1.05	0.09	4.95	0.35
7.5	1.56	0.28	9.56	0.17
10.0	3.33	0.33	13.40	0.37
12.5	5.40	0.48	15.30	0.46
15.0	6.26	0.18	18.62	0.43
	НСТ		HCTTi	
5.0	0.12	0.02	0.31	0.06
7.5	0.18	0.03	0.48	0.16
10.0	0.23	0.06	1.18	0.13
12.5	0.23	0.06	1.43	0.07
15.0	0.28	0.03	3.19	0.30

Table 7. Disintegration time of the API and API-TNT tablets